Table 1 Demographics and ongoing treatment in 93 Sudanese and 332 Swedish SLE patients.

From: Accumulation of antinuclear associated antibodies in circulating immune complexes is more prominent in SLE patients from Sudan than Sweden

Demographics and treatment

Sudan

Sweden

P value

Gender (F%)

96.8%

88.1%

0.01

Age at inclusion (median/mean) Years

35/36

47.7/46.8

 < 0.0001

Duration of disease (median/mean) Years

4/4.9

15/17.9

 < 0.0001

SLEDAI score (median/mean)

0/1.7

0/1.7

0.4

Hydroxychloroquine n (%)

49 (54.4%)

113 (34.6%)

0.0006

Prednisolone n (%)

61 (67.8%)

188 (57.1%)

0.06

Prednisolone dose

(median/mean) mg

5.0/10.0

2.5/5

0.01

Any DMARDS at inclusion n (%)

73 (81.1%)

105 (35.6%)

 < 0.0001

Azathioprine n (%)

59 (65.6%)

56 (17.2%)

 < 0.0001

Mycophenolate mofetil n (%)

12 (13.3%)

32 (9.9%)

0.3

Methotrexate n (%)

8 (8.9%)

14 (4.3%)

0.08

Cyclophosphamide n (%)

2 (2.2%)

4 (1.4%)

0.6

Cyclosporine n (%)

1(1.1%)

2 (0.6%)

0.6

  1. Significant P values are depicted in bold and underlined to indicate higher prevalence in Sudanese patients.
  2. DMARDS disease modifying anti-rheumatic drugs (azathioprine, mycophenolate mofetil, methotrexate, cyclophosphamide and cyclosporine), F female.
Back to article page